Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor

Core Insights - CancerVax, Inc. has appointed Dr. George Kemble as Senior Scientific Advisor to enhance its universal cancer treatment platform that utilizes the immune system to combat cancer [1][6]. Company Overview - CancerVax is a pre-clinical biotech company focused on developing a customizable universal cancer treatment platform that aims to detect, mark, and kill only cancer cells [6]. - The company's innovative approach involves disguising cancer cells to resemble well-immunized common diseases, such as measles or chickenpox, to leverage the body's natural immune response [4][6]. Leadership and Expertise - Dr. George Kemble is a seasoned biotech executive with extensive experience in virology, vaccines, and small molecule biologics, previously serving as Chairman of the Board at Sagimet Biosciences Inc. [2]. - His background includes significant roles at MedImmune, where he led research and development efforts, including the launch of FluMist®, the first major innovation in influenza vaccines in over 60 years [3]. Strategic Vision - Dr. Kemble's appointment is expected to bring valuable insights into translating immunology into effective therapies, aligning with CancerVax's mission to reframe cancer as a target the immune system can recognize and defeat [5].